ABVC BioPharma, Inc.
ABVC Healthcare Biotechnology
ABVC BioPharma, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $509,600.00, up 234.4% from fiscal 2023. In the quarter to June 2026, revenue grew 66,233.3%, EPS grew 76.9% and free cash flow grew 72.7%, each against the same quarter a year earlier.
Follow ABVC
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
0.92 | 1.39 | 0.20 | 0.09 |
Receivables |
— | 0.76 | 0.20 | — | |
Inventory |
0.01 | — | — | — | |
Other current assets |
1.93 | 0.76 | — | 0.14 | |
Total current assets |
3.31 | 2.50 | 0.65 | 0.41 | |
Property, Plant, Equpment (Net) |
12.85 | 12.84 | 12.82 | 12.83 | |
Long-Term Investments |
3.87 | 3.00 | 3.64 | 3.61 | |
Long-term assets (Other) |
0.81 | 0.81 | 0.80 | 0.80 | |
Total non-current assets |
17.90 | 18.56 | 19.08 | 18.99 | |
Total Assets |
21.21 | 21.06 | 19.73 | 19.40 | |
Notes Payable |
1.03 | 1.55 | 0.89 | 0.86 | |
Accrued Expenses |
3.99 | 4.16 | 4.15 | 4.20 | |
Current Part of Taxes to Pay |
0.01 | 0.01 | 0.01 | — | |
Other current liabilities |
1.32 | 0.01 | 0.01 | 0.01 | |
Total current liabilities |
6.54 | 6.16 | 5.39 | 5.69 | |
Non-current Liabilities (Other) |
0.01 | — | — | 0.03 | |
Total non-current liabilities |
0.18 | 1.60 | 1.51 | 1.44 | |
Total liabilities |
6.72 | 7.76 | 6.90 | 7.13 | |
Additional Paid In Capital |
93.91 | 96.01 | 97.15 | 97.72 | |
Common Stock (Net) |
0.02 | 0.03 | 0.03 | 0.03 | |
Retained Earnings |
(74.09) | (76.86) | (78.42) | (79.16) | |
Treasury Stock |
8.91 | 8.91 | 8.91 | 8.91 | |
Shareholders Equity (Other) |
0.64 | 0.36 | 0.42 | 0.11 | |
Common Equity (Total) |
14.50 | 13.30 | 12.83 | 12.27 | |
Shareholders Equity (Total) |
14.50 | 13.30 | 12.83 | 12.27 | |
Shareholders Equity and Liabilities (Total) |
21.21 | 21.06 | 19.73 | 19.40 | |
Shares (Common) |
24.19 | 24.32 | 25.04 | 25.49 | |
Shares (Preferred) |
— | 0.00 | — | 0.00 | |
Shareholders Equity (Tangible) |
14.50 | 13.30 | 12.83 | 12.27 | |
Net Debt |
(0.92) | (1.39) | (0.20) | (0.09) |